| Michael Patrick Allen, DO | |
|
350 Terracina Blvd, Redlands, CA 92373-4850 | |
| (909) 335-5500 | |
| Not Available |
| Full Name | Michael Patrick Allen |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 8 Years |
| Location | 350 Terracina Blvd, Redlands, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508216532 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 5151012734 (Michigan) | Secondary |
| 207P00000X | Emergency Medicine | 20A18211 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Redlands Community Hospital | Redlands, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cep America - California | 6103739131 | 954 |
News Archive
Scientists have identified the gene responsible for one type of Charcot-Marie-Tooth disorder, a common inherited neurological disease, thanks to the chance appearance of a strain of impaired 'pale tremor' mice in a University of Michigan research laboratory.
A new article in the February issue of the Journal of the American College of Radiology provides a roadmap for imaging manufacturers to navigate the unique and increasingly complex U.S. regulatory and reimbursement environment. "Evidence Requirements for Innovative Imaging Devices: From Concept to Adoption," identifies and addresses the five phases of an imaging procedure's lifecycle and the distinct clinical evidence needs for each phase.
In a remarkably rapid translation of laboratory research findings into a treatment with the potential to benefit patients, UC San Francisco scientists have successfully completed a Phase II clinical trial showing that an FDA-approved antihistamine restores nervous system function in patients with chronic multiple sclerosis (MS).
DARA BioSciences, Inc., a development-stage pharmaceutical company, today announced that it has entered into a definitive agreement with several institutional investors to sell 612,667 units, with each unit consisting of one of the Company's common shares and 0.50 warrants to purchase one share of common stock, for gross proceeds of approximately $1.4 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering.
› Verified 7 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023063542 PECOS PAC ID: 6103739131 Enrollment ID: O20031106000520 |
News Archive
Scientists have identified the gene responsible for one type of Charcot-Marie-Tooth disorder, a common inherited neurological disease, thanks to the chance appearance of a strain of impaired 'pale tremor' mice in a University of Michigan research laboratory.
A new article in the February issue of the Journal of the American College of Radiology provides a roadmap for imaging manufacturers to navigate the unique and increasingly complex U.S. regulatory and reimbursement environment. "Evidence Requirements for Innovative Imaging Devices: From Concept to Adoption," identifies and addresses the five phases of an imaging procedure's lifecycle and the distinct clinical evidence needs for each phase.
In a remarkably rapid translation of laboratory research findings into a treatment with the potential to benefit patients, UC San Francisco scientists have successfully completed a Phase II clinical trial showing that an FDA-approved antihistamine restores nervous system function in patients with chronic multiple sclerosis (MS).
DARA BioSciences, Inc., a development-stage pharmaceutical company, today announced that it has entered into a definitive agreement with several institutional investors to sell 612,667 units, with each unit consisting of one of the Company's common shares and 0.50 warrants to purchase one share of common stock, for gross proceeds of approximately $1.4 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Patrick Allen, DO 350 Terracina Blvd, Redlands, CA 92373-4897 Ph: (909) 335-5500 | Michael Patrick Allen, DO 350 Terracina Blvd, Redlands, CA 92373-4850 Ph: (909) 335-5500 |
News Archive
Scientists have identified the gene responsible for one type of Charcot-Marie-Tooth disorder, a common inherited neurological disease, thanks to the chance appearance of a strain of impaired 'pale tremor' mice in a University of Michigan research laboratory.
A new article in the February issue of the Journal of the American College of Radiology provides a roadmap for imaging manufacturers to navigate the unique and increasingly complex U.S. regulatory and reimbursement environment. "Evidence Requirements for Innovative Imaging Devices: From Concept to Adoption," identifies and addresses the five phases of an imaging procedure's lifecycle and the distinct clinical evidence needs for each phase.
In a remarkably rapid translation of laboratory research findings into a treatment with the potential to benefit patients, UC San Francisco scientists have successfully completed a Phase II clinical trial showing that an FDA-approved antihistamine restores nervous system function in patients with chronic multiple sclerosis (MS).
DARA BioSciences, Inc., a development-stage pharmaceutical company, today announced that it has entered into a definitive agreement with several institutional investors to sell 612,667 units, with each unit consisting of one of the Company's common shares and 0.50 warrants to purchase one share of common stock, for gross proceeds of approximately $1.4 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering.
› Verified 7 days ago
Gordon D Phillips, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 W Fern Ave, Redlands, CA 92373 Phone: 909-793-3311 Fax: 909-793-2916 | |
Jonathan A E Bolton, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 245 Terracina Blvd Ste 102, Redlands, CA 92373 Phone: 909-335-4188 | |
Pha C Le, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1260 Magnolia Ave, Redlands, CA 92373 Phone: 714-566-5235 | |
Julee Ann Brice, P.A-C Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 25828 Redlands Blvd, Suite 102, 103, Redlands, CA 92373 Phone: 909-806-1598 Fax: 909-887-1985 | |
James Wilson, M.D Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 350 Terracina Blvd, Redlands, CA 92373 Phone: 909-335-5500 | |
Phong Ky Nguyen, M.D Emergency Medicine Medicare: Medicare Enrolled Practice Location: 350 Terracina Blvd, Redlands, CA 92373 Phone: 909-335-5500 |